Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R de Wit

Showing results (111-120 of 147) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research CouncilR de Wit, J T Roberts, P M Wilkinson, et al.
British Journal of Cancer|June 1, 1995
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative GroupR de Wit, G Stoter, D T Sleijfer, et al.
Journal of the National Cancer Institute|May 26, 1999
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working PartyL Collette, R J Sylvester, S P Stenning, et al.
British Journal of Cancer|October 28, 2005
Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)S D Fosså, B Paluchowska, A Horwich, et al.
Investigational New Drugs|May 4, 2004
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumorsM J A de Jonge, J P Droz, L Paz-Ares, et al.
Radiology|May 5, 2000
Retroperitoneal metastases in testicular cancer: role of CT measurements of residual masses in decision making for resection after chemotherapyE W Steyerberg, H J Keizer, D T Sleijfer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2000
A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remissionS Rodenhuis, R de Wit, P H de Mulder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patientsW P Steward, J von Pawel, U Gatzemeier, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2013
Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate StudyF L Gerritse, H J Meulenbeld, J M L Roodhart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2014
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trialsR J van Soest, A J Templeton, F E Vera-Badillo, et al.
Pageof 15

Showing results (111-120 of 147) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research CouncilR de Wit, J T Roberts, P M Wilkinson, et al.
British Journal of Cancer|June 1, 1995
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative GroupR de Wit, G Stoter, D T Sleijfer, et al.
Journal of the National Cancer Institute|May 26, 1999
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working PartyL Collette, R J Sylvester, S P Stenning, et al.
British Journal of Cancer|October 28, 2005
Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)S D Fosså, B Paluchowska, A Horwich, et al.
Investigational New Drugs|May 4, 2004
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumorsM J A de Jonge, J P Droz, L Paz-Ares, et al.
Radiology|May 5, 2000
Retroperitoneal metastases in testicular cancer: role of CT measurements of residual masses in decision making for resection after chemotherapyE W Steyerberg, H J Keizer, D T Sleijfer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2000
A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remissionS Rodenhuis, R de Wit, P H de Mulder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patientsW P Steward, J von Pawel, U Gatzemeier, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2013
Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate StudyF L Gerritse, H J Meulenbeld, J M L Roodhart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2014
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trialsR J van Soest, A J Templeton, F E Vera-Badillo, et al.
Pageof 15